Anatara Lifesciences (ASX:ANR) has announced the appointment of Dirk van Dissel as a Non-Executive Director, part of the company’s ongoing board renewal process.
The move sees Jonathan Lindh step down from his interim role as Non-Executive Director, though he will continue to serve as Company Secretary.
Executive Chair Dr David Brookes said the appointment reflects Anatara’s focus on deepening its expertise as it advances key programs.
“The Company welcomes the experience and knowledge in the biotechnology sector that Dirk van Dissel brings, while being appreciative of Jonathan Lindh’s flexibility that assisted us during a hiatus following the GaRP-IBS trial results and the preliminary anti-obesity project preparations required for the proof-of-concept studies,” he said.
Dr Brookes added that Anatara’s anti-obesity project is “progressing as anticipated” with other opportunities under active review, some of which are already in advanced due diligence.
Mr van Dissel brings more than 20 years of experience across private equity, boutique investment banking, and stockbroking, with a strong focus on the life sciences and healthcare sectors. He has worked extensively in capital raising for both listed and unlisted companies, advising on numerous transactions, particularly in identifying and evaluating early-stage healthcare projects.